See the DrugPatentWatch profile for jornay
Information regarding a generic version of Jornay PM is not readily available. Jornay PM is a prescription medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged 6 and older [1].
When might a generic version become available?
The availability of generic drugs is typically tied to patent expiration and the successful challenge or expiry of exclusivity periods. Patent information for specific drugs can be tracked to anticipate potential generic entry. DrugPatentWatch.com provides resources for monitoring drug patents and exclusivity [2].
What is Jornay PM and how does it work?
Jornay PM is a methylphenidate hydrochloride extended-release capsule [1]. It is designed to be taken in the evening and works by affecting the levels of certain natural substances in the brain that are associated with hyperactivity and impulsivity [1]. The extended-release formulation allows for a once-daily evening dose [1].
What are the approved uses for Jornay PM?
Jornay PM is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients 6 years of age and older [1].
What are the potential side effects of Jornay PM?
Common side effects of Jornay PM may include decreased appetite, trouble sleeping, nausea, vomiting, and weight loss [1]. More serious side effects can include psychological symptoms such as new or worsening behavioral or thought problems, and circulation problems in fingers and toes [1]. It is important for patients to discuss potential side effects with their healthcare provider [1].
How does Jornay PM compare to other ADHD medications?
Jornay PM is a specific formulation of methylphenidate, a stimulant medication. It differs from other methylphenidate products and ADHD treatments primarily in its extended-release mechanism and evening dosing recommendation [1]. Comparisons with other ADHD medications would depend on the specific drug and its formulation.
What is the regulatory status of Jornay PM?
Jornay PM is approved by the U.S. Food and Drug Administration (FDA) for its indicated use in treating ADHD [1].
What companies are involved with Jornay PM?
Ironshore Pharmaceuticals is the manufacturer of Jornay PM [1].
What are the current patents protecting Jornay PM?
Specific patent details for Jornay PM would be available through patent databases. Monitoring these patents is crucial for understanding potential generic entry timelines [2].
What clinical data supports Jornay PM's efficacy?
Clinical trials have been conducted to assess the efficacy and safety of Jornay PM in treating ADHD [1]. The data from these trials informs its approved use and prescribing information.
What are patient considerations when taking Jornay PM?
Patients prescribed Jornay PM should follow their doctor's instructions regarding dosage and administration, particularly the evening dosing schedule [1]. Regular monitoring for side effects and efficacy is also important. Patients should inform their healthcare provider of any pre-existing medical conditions or other medications they are taking [1].
Sources:
1. https://www.na.jornaypm.com/
2. https://drugpatentwatch.com/